Understanding Nanoparticle Uptake by Human Corneal Epithelial Cells

Study Background and Research Question

Topical ocular drug delivery remains a major challenge due to the eye's natural protective barriers. The cornea, and particularly its epithelial layer, provides formidable resistance to drug penetration, leading to low bioavailability for most eye medications. Traditional approaches to enhance drug absorption—such as viscosity enhancers, penetration enhancers, and in situ gels—can increase residence time but often cause irritation, blurred vision, or other side effects. Consequently, polymeric nanoparticles have attracted significant interest for their potential to overcome these limitations by improving drug retention, penetration, and release profiles. However, the exact interplay between nanoparticle properties—such as size and surface chemistry—and their cellular uptake by corneal epithelial cells has remained incompletely understood. The reference study addresses this gap by systematically examining how engineered nanoparticles interact with human corneal epithelial cells (HCECs) and identifying the pathways responsible for their uptake (reference study).

Key Innovation from the Reference Study

The core innovation of this work lies in its rigorous, comparative analysis of how the physicochemical characteristics of nanoparticles affect their internalization by HCECs. By synthesizing poly(lactic-co-glycolic) acid (PLGA) nanoparticles with well-controlled sizes and surface modifications, the authors dissect the contributions of particle dimension and surface chemistry to uptake mechanisms. The study further leverages specific chemical inhibitors to delineate the endocytic pathways involved, providing a mechanistic foundation for rational nanoparticle design in ocular drug delivery. This clarity on uptake mechanisms is pivotal for developing next-generation nanomedicines that efficiently traverse the ocular surface barriers without inducing cytotoxicity or irritation.

Methods and Experimental Design Insights

The researchers fabricated PLGA nanoparticles using the emulsion-solvent evaporation method, yielding spherical and monodisperse particles with polydispersity indices (PDI) below 0.2. Nanoparticles were engineered with diameters ranging from 100 to 250 nm and zeta potentials between -25 and +15 mV. Surface functionalization was achieved with mucoadhesive polymers (alginate [ALG] and chitosan [CHS]) and a mucopenetrative polymer (polyethylene glycol [PEG]). All formulations were characterized for size distribution, surface charge, and morphology.

Cytotoxicity was assessed using the MTT assay following 24-hour incubation with nanoparticles at concentrations up to 100 μg/mL, a range relevant for in vitro ocular applications. To model physiological conditions, HCECs were cultured as a monolayer and exposed to a simulated mucosal solution, mimicking the tear film and mucus environment of the ocular surface. Uptake studies were performed using fluorescence-labeled nanoparticles, and the effect of various endocytosis inhibitors was systematically evaluated to map the predominant internalization pathways.

Core Findings and Why They Matter

Several significant discoveries emerge from the study:

• Safety Profile: Exposure to PLGA nanoparticles up to 100 μg/mL for 24 hours preserved cell viability at 70–100%, indicating mild cytotoxicity and supporting the feasibility of these carriers for ocular use.
• Uptake Mechanisms: Cellular uptake of nanoparticles was found to be energy-dependent, with macropinocytosis and caveolae-mediated endocytosis identified as the dominant routes. Clathrin-mediated endocytosis contributed partially, whereas phagocytosis was negligible within the tested size and surface property ranges (reference study).
• Particle Size and Surface Chemistry: The highest uptake was observed for 100 nm PLGA nanoparticles and PEG-PLGA-150 formulations, underscoring the importance of optimizing both size and surface chemistry for maximal delivery efficiency.
• Barrier Implications: By mapping the uptake mechanisms, the study provides actionable parameters for designing nanoparticle formulations that can bypass the epithelial barrier more effectively, potentially reducing the dose and frequency required for therapeutic efficacy.

Comparison with Existing Internal Articles

Recent internal resources have explored the use of actin polymerization inhibitors such as Cytochalasin D (SKU B6645) for dissecting cellular uptake and endocytosis pathways in vitro. For example, "Cytochalasin D: Pioneering Cytoskeletal Disruption for Translational Research" discusses the pivotal role of actin dynamics in cellular internalization processes, including macropinocytosis and caveolae-mediated endocytosis. These articles offer protocol recommendations and troubleshooting tips for using Cytochalasin D to selectively disrupt actin microfilaments, thereby clarifying the role of the cytoskeleton in nanoparticle trafficking. By bridging mechanistic insights from cytoskeletal research to ocular models, these resources complement the reference study’s findings and provide practical workflow guidance for researchers aiming to interrogate nanoparticle uptake pathways in similar epithelial systems.

Furthermore, internal articles such as "Cytochalasin D as an Actin Polymerization Inhibitor: Applied Workflows" outline how actin polymerization inhibitors can help distinguish between endocytic routes, supporting the conclusion that actin-dependent mechanisms are central to nanoparticle internalization in ocular epithelial cells.

Limitations and Transferability

While the study offers strong evidence for the mechanistic underpinnings of nanoparticle uptake in vitro, several limitations should be considered. First, the in vitro HCEC monolayer and simulated mucosal environment, though physiologically relevant, cannot fully recapitulate the complexity of the in vivo ocular surface, including dynamic tear turnover and multi-layered tissue interactions. The use of chemical inhibitors, while informative, may have off-target effects that complicate interpretation of endocytic pathways. Moreover, the findings may not directly translate to other epithelial cell types or non-polymeric nanoparticle systems. Therefore, while the design principles elucidated here are valuable, further validation in animal models and across diverse nanoparticle chemistries is required before clinical translation.

Why this cross-domain matters, maturity, and limitations

The intersection of nanoparticle engineering and cytoskeletal modulation is highly relevant for ocular drug delivery, as actin dynamics play a critical role in endocytosis and barrier function. The ability to modulate or probe these pathways using actin polymerization inhibitors such as Cytochalasin D enables researchers to dissect the relative contributions of uptake mechanisms and to design carriers that maximize therapeutic delivery. However, translating these in vitro insights to in vivo or clinical settings requires careful consideration of potential toxicity, off-target effects, and the unique physiology of the ocular surface. The maturity of this cross-domain approach is supported by convergent findings from both the reference study and internal resources, but its limitations must be addressed through ongoing research and validation.

Protocol Parameters

• Nanoparticle synthesis: PLGA nanoparticles prepared via emulsion-solvent evaporation; target size range 100–250 nm for optimal uptake by HCECs.
• Surface functionalization: Use mucoadhesive or mucopenetrative polymers (e.g., alginate, chitosan, PEG) to modulate zeta potential and uptake behavior.
• Cell culture: HCECs grown to confluence as monolayer; integrate simulated mucosal solution to mimic ocular surface conditions.
• Cytotoxicity testing: MTT assay after 24 h exposure to nanoparticles at 10–100 μg/mL; maintain cell viability above 70% for formulation acceptance.
• Uptake pathway interrogation: Pre-treat cells with specific inhibitors (e.g., Cytochalasin D for actin-dependent pathways) to dissect contributions of macropinocytosis, caveolae- and clathrin-mediated endocytosis.

Research Support Resources

For researchers seeking to probe actin-dependent uptake mechanisms in ocular or other epithelial systems, reagents such as Cytochalasin D (SKU B6645) offer a validated and selective means to inhibit actin polymerization at nanomolar concentrations. Literature-backed protocols suggest using concentrations between 0.2 and 0.5 μg/mL for cell culture applications, with prompt preparation and use due to limited solution stability. APExBIO provides detailed product specifications and troubleshooting guidance for such applications, supporting reproducible and robust experimental workflows.